Funding for this research was provided by:
NIHR HTA (07.01.14)
Text and Data Mining valid from 2018-05-10
Received: 6 October 2016
Accepted: 26 April 2018
First Online: 10 May 2018
Ethics approval and consent to participate
: The study was approved by Wandsworth Research Ethics Committee (reference 08/H0803/177). All participants provided written informed consent.
: All authors have completed the ICMJE uniform disclosure form at and declare: no support from any organisation for the submitted work; in the past three years PA has done one day of consultancy for Pfizer concerning general smoking cessation advice and not about particular products and RW has undertaken research and consultancy for companies (Pfizer and GSK) that develop and manufacture smoking cessation drugs; in the past three years TC has been paid for speaking at two educational events that were part or wholly sponsored by a company (Pierre Fabre Laboratories, France) that manufactures nicotine replacement therapy; RW is an unpaid trustee of the stop smoking charity QUIT and an unpaid director of the National Centre for Smoking Cessation and Training; there are no other relationships or activities that could appear to have influenced the submitted work.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.